AI assistant
ImageneBio, Inc. — Director's Dealing 2021
Nov 24, 2021
34275_dirs_2021-11-23_ef258678-76f5-47c8-a084-613d1c63e07a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-11-22
Reporting Person: Zhang Xiaoyan Michelle (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 44475 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $2.1462 | 2028-12-17 | Common Stock (26473) | Direct | |
| Stock Option (Right to Buy) | $4.1493 | 2029-03-19 | Common Stock (35792) | Direct | |
| Stock Option (Right to Buy) | $4.1493 | 2029-10-17 | Common Stock (19427) | Direct | |
| Stock Option (Right to Buy) | $7.8694 | 2031-02-11 | Common Stock (55912) | Direct |
Footnotes
F1: 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F2: 25% of the shares subject to this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3: 25% of the shares subject to this option vested and became exercisable on September 30, 2020 with the remainder vesting in 36 substantially equal monthly installments thereafter.
F4: 25% of the shares subject to this option shall vest and become exercisable on February 12, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.